We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
Read MoreHide Full Article
Key Takeaways
Immuneering rose 21.7% after a supply deal with Eli Lilly for its KRAS G12C inhibitor.
The phase II study will test atebimetinib with olomorasib in advanced KRAS G12C lung cancer.
Immuneering also partnered with Regeneron to test atebimetinib with Libtayo in NSCLC.
Immuneering Corporation (IMRX - Free Report) announced that it has entered into a clinical supply agreement with pharma giant Eli Lilly (LLY - Free Report) for the latter’s second-generation KRAS G12C inhibitor, olomorasib (LY3537982).
The agreement supports a planned phase II study that will evaluate Immuneering’s lead product candidate, atebimetinib (IMM-1-104), a dual MEK inhibitor, in combination with Lilly’s olomorasib for treating patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (“NSCLC”), whose disease has progressed on prior treatment.
Shares of Immuneering were up 21.7% yesterday following the announcement of the news.
The stock has skyrocketed 170.5% so far this year compared with the industry’s rise of 4.1%.
Image Source: Zacks Investment Research
Per management, the combination of atebimetinib plus olomorasib has the potential to provide a vertical blockade of the RAS-MAPK pathway. Data from preclinical studies demonstrated that treatment with atebimetinib plus olomorasib can lead to enhanced tumor regression, delayed resistance and prolonged survival compared with monotherapy.
The latest agreement with LLY marks Immuneering’s second collaboration announcement in 2025.
IMRX's Similar Agreement With Regeneron
In February 2025, the company entered into a similar kind of agreement with Regeneron Pharmaceuticals (REGN - Free Report) to evaluate atebimetinib in combination with the latter’s anti-PD-1 therapy Libtayo (cemiplimab) for treating patients with advanced NSCLC in an ongoing phase IIa study.
Per this agreement, Immuneering will fund the planned studies while Regeneron will supply Libtayo, which is approved for various types of cancer indications.
In both the Lilly and Regeneron agreements, Immuneering will retain full worldwide development and commercialization rights to atebimetinib.
Recent Developments Related to IMRX's Atebimetinib
Immuneering is already advancing atebimetinib in other cancer studies. A phase IIa study is evaluating atebimetinib in combination with chemotherapy (modified gemcitabine/nab-paclitaxel) in first-line pancreatic cancer.
Data from the study announced in June showed that the combination of atebimetinib plus modified gemcitabine/nab-paclitaxel led to a 94% overall survival (“OS”) and 72% progression-free survival (“PFS”) at six months for the given indication. The median OS and PFS have not yet been reached.
Updated OS and PFS data from the study evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients are expected to be announced later in the third quarter of 2025.
Pending regulatory feedback, Immuneering plans to initiate a pivotal study evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients in 2026.
In the absence of an approved product, pipeline development remains in key focus for the company.
Image: Shutterstock
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
Key Takeaways
Immuneering Corporation (IMRX - Free Report) announced that it has entered into a clinical supply agreement with pharma giant Eli Lilly (LLY - Free Report) for the latter’s second-generation KRAS G12C inhibitor, olomorasib (LY3537982).
The agreement supports a planned phase II study that will evaluate Immuneering’s lead product candidate, atebimetinib (IMM-1-104), a dual MEK inhibitor, in combination with Lilly’s olomorasib for treating patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (“NSCLC”), whose disease has progressed on prior treatment.
Shares of Immuneering were up 21.7% yesterday following the announcement of the news.
The stock has skyrocketed 170.5% so far this year compared with the industry’s rise of 4.1%.
Image Source: Zacks Investment Research
Per management, the combination of atebimetinib plus olomorasib has the potential to provide a vertical blockade of the RAS-MAPK pathway. Data from preclinical studies demonstrated that treatment with atebimetinib plus olomorasib can lead to enhanced tumor regression, delayed resistance and prolonged survival compared with monotherapy.
The latest agreement with LLY marks Immuneering’s second collaboration announcement in 2025.
IMRX's Similar Agreement With Regeneron
In February 2025, the company entered into a similar kind of agreement with Regeneron Pharmaceuticals (REGN - Free Report) to evaluate atebimetinib in combination with the latter’s anti-PD-1 therapy Libtayo (cemiplimab) for treating patients with advanced NSCLC in an ongoing phase IIa study.
Per this agreement, Immuneering will fund the planned studies while Regeneron will supply Libtayo, which is approved for various types of cancer indications.
In both the Lilly and Regeneron agreements, Immuneering will retain full worldwide development and commercialization rights to atebimetinib.
Recent Developments Related to IMRX's Atebimetinib
Immuneering is already advancing atebimetinib in other cancer studies. A phase IIa study is evaluating atebimetinib in combination with chemotherapy (modified gemcitabine/nab-paclitaxel) in first-line pancreatic cancer.
Data from the study announced in June showed that the combination of atebimetinib plus modified gemcitabine/nab-paclitaxel led to a 94% overall survival (“OS”) and 72% progression-free survival (“PFS”) at six months for the given indication. The median OS and PFS have not yet been reached.
Updated OS and PFS data from the study evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients are expected to be announced later in the third quarter of 2025.
Pending regulatory feedback, Immuneering plans to initiate a pivotal study evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients in 2026.
In the absence of an approved product, pipeline development remains in key focus for the company.
Immuneering Corporation Price
Immuneering Corporation price | Immuneering Corporation Quote
IMRX's Zack Rank
Immuneering currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.